Published: 30 April 2015
Author(s): Rolf P. Engelberger, Georg Noll, Dominique Schmidt, Adriano Alatri, Benedikt Frei, Walter E. Kaiser, Nils Kucher
Section: Original Article

Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk–benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.